Nkarta
Nkarta reported revenue of $0 million in fiscal 2025. Free cash flow was −$90 million. The diluted share count rose 9.0%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Nkarta lost money in fiscal 2025: a net loss of $104 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 238 | 352 | 248 | 267 | 276 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 19.0x | 16.4x | 10.8x | 14.4x | 12.7x |
| Quick ratio | 19.0x | 16.4x | 10.8x | 14.4x | 12.7x |
Cash flow
Projections
Project Nkarta's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Nkarta shares on the open market, and 2 insiders sold $70,421.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 18, 2026 | Paul J HastingsChief Executive Officer, Director | Sold | 1,776 | $2.71 | $4,813 | Form 4 |
| Jan 15, 2026 | Paul J HastingsChief Executive Officer, Director | Sold | 26,046 | $2.07 | $53,915 | Form 4 |
| Jan 15, 2026 | Nadir MahmoodPresident | Sold | 5,649 | $2.07 | $11,693 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | 0.61 | 2.67 | 0.54 |
| Accruals ratio | −7.4% | −2.1% | −3.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | Fail |
| F-score | — | — | — |
Compare
Put Nkarta side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Nkarta | FY25 | — | — | — | — | — | — | |
| Aardvark Therapeutics | FY25 | — | — | — | — | — | — | Compare |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0 | — | — | — | — | 0 | 0 |
| Revenue growth | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 17 | 36 | 63 | 91 | 97 | 97 | 90 |
| Operating income | −22 | −52 | −86 | −119 | −132 | −128 | −122 |
| Net income | −21 | −91 | −86 | −114 | −118 | −109 | −104 |
| Diluted EPS (US$) | −14.41 | −5.44 | −2.62 | −2.61 | −2.40 | −1.60 | −1.41 |
| Diluted shares (millions) | 2 | 17 | 33 | 44 | 49 | 68 | 74 |
| Cash flow | |||||||
| Cash from operations | −18 | −44 | −68 | −57 | −86 | −100 | −89 |
| Capital expenditure | 2 | 8 | 5 | 47 | 28 | 4 | 1 |
| Free cash flow | −20 | −51 | −73 | −104 | −114 | −104 | −90 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 7 | 14 | 17 | 17 | 17 | 9 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 37 | 315 | 238 | 352 | 248 | 267 | 276 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | 48 | 338 | 274 | 473 | 379 | 501 | 404 |
| Total liabilities | 14 | 16 | 23 | 101 | 106 | 93 | 92 |
| Shareholders' equity | −26 | 321 | 251 | 372 | 273 | 408 | 312 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | −19,433.9% | — | — | — | — | — | — |
| Net margin | −18,327.0% | — | — | — | — | — | — |
| Free cash flow margin | −17,647.8% | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | −61.8% | −30.1% | −36.5% | −36.4% | −31.9% | −28.9% |
| Return on assets | — | −47.3% | −28.1% | −30.5% | −27.6% | −24.7% | −23.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — |